Skip to main content

Lakewood-Amedex Biotherapeutics Inc.

corporate_fare Company Profile

Lakewood-Amedex Biotherapeutics Inc.

LABT·NASDAQ·Life Sciences·CIK 0002079272

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing antimicrobial products in the United States. The company's primary offerings include products from its Bisphosphocin class, which are a novel type of antimicrobial agents designed to combat infections by disrupting the membranes of microbes. Additionally, Lakewood-Amedex Biotherapeutics Inc. is developing Nu-3, a topical antimicrobial specifically intended for treating infected diabetic foot ulcers. The company, originally incorporated in 2006, was formerly known as Lakewood-Amedex Inc. and adopted its current name, Lakewood-Amedex Biotherapeutics, Inc., in June 2025. Its headquarters are located in University Park, Florida.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LABT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Lakewood-Amedex Secures CRO for Nu-3 Phase 2 Trial, Advancing Lead Candidate
  • Selling Stockholders Register Over 9.6M Shares for Resale, Posing Significant Dilution Risk Amidst Going Concern Warning
  • Lead Candidate NU-3 Shows Strong Antimicrobial Resistance Data for Diabetic Foot Ulcers
  • Lakewood-Amedex Appoints Biotech Veteran Dr. Joseph Tucker to Board, Bolstering Capital Markets Expertise
$0.235 -4.04% today
52-week range · as of 2026-11-16 $0.1687 – $98.2
Market cap
$2.19M
Volume
57.7M (1.8× avg)
3-mo avg 32M
Live data · 2026-11-21 19:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LABT - Filings & News (Page 2)

LABT
May 12, 2026, 8:02 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $3.16
Real-time Price: $0.235 info
Change: Reverse Stock Split info
Market Cap: $2.192M info
LABT
May 01, 2026, 4:05 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $3.27
Real-time Price: $0.235 info
Change: Reverse Stock Split info
Market Cap: $2.192M info
LABT
May 01, 2026, 9:33 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.22
Real-time Price: $0.235 info
Change: Reverse Stock Split info
Market Cap: $2.192M info
LABT
Apr 28, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.95
Real-time Price: $0.235 info
Change: Reverse Stock Split info
Market Cap: $2.192M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets